Last update April 16, 2024
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Spirapril Hydrochloride in other languages or writings:
Spirapril Hydrochloride belongs to these groups or families:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 45 - 50 | % |
Molecular weight | 503 | daltons |
Protein Binding | 89 | % |
VD | 0.4 - 0.6 | l/Kg |
pKa | 3.62 | - |
Tmax | 2 - 3 | hours |
T½ | 30 - 35 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Spirapril and its active metabolite spiraprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension. Oral administration once day.
At the time of the last update, we found no published data on its excretion in breast milk.
Other compounds in the same group (ACEI) are not significantly excreted in breast milk, but until further published data on this drug in relation to breastfeeding are known safer alternatives may be preferable. (Anderson 2018)
Due to its potential renal toxicity in premature infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015)
The protective role of breastfeeding against maternal hypertension has been proven. (Park 2018)